Compare AbbVie Inc (ABBV) vs Vistra Corp (VST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Vistra Corp — how do they compare? AbbVie Inc trades at $253.85 (market cap $449.91B), while Vistra Corp trades at $152.42 (market cap $52.51B). The key difference: AbbVie Inc is far larger — about 8.6× Vistra Corp's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | VST | |
|---|---|---|
Market Cap | $449.91B | $52.51B |
Sector | Health | Technology |
52-Week High | $261.07 | $217.92 |
52-Week Low | $184.85 | $134.71 |
Enterprise Value | $513.38B | $74.26B |
Dividend Yield | 2.72% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Vistra Corp (VST) trades at $157.22, up 4.08% with a bearish technical signal despite strong analyst support. The stock shows mixed earnings performance with recent beats but faces cash flow challenges. Revenue growth from $17.74B to $19.4B and improved net margins to 11.52% reflect operational strength, supported by AI-driven power demand catalysts and a $6.3B buyback program.
Outlook remains positive with 91% analyst buy ratings and a $230.50 price target, though technical resistance near $159 and volatile earnings pose near-term risks. Long-term growth is fueled by nuclear/renewable expansion, but investors should monitor execution on guidance and energy market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
